[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PT1163239E - Amidas de aminoacidos modificadas como antagonistas do cgrp - Google Patents

Amidas de aminoacidos modificadas como antagonistas do cgrp

Info

Publication number
PT1163239E
PT1163239E PT00922505T PT00922505T PT1163239E PT 1163239 E PT1163239 E PT 1163239E PT 00922505 T PT00922505 T PT 00922505T PT 00922505 T PT00922505 T PT 00922505T PT 1163239 E PT1163239 E PT 1163239E
Authority
PT
Portugal
Prior art keywords
amended
amino acids
cgrp antagonists
cgrp
antagonists
Prior art date
Application number
PT00922505T
Other languages
English (en)
Inventor
Henri Doods
Eberlein Dr Wolfgang
Engel Dr Wolfhard
Gerhard Hallermayer
Klaus Rudolf
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of PT1163239E publication Critical patent/PT1163239E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT00922505T 1999-03-12 2000-03-08 Amidas de aminoacidos modificadas como antagonistas do cgrp PT1163239E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19911039A DE19911039A1 (de) 1999-03-12 1999-03-12 Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
PT1163239E true PT1163239E (pt) 2003-10-31

Family

ID=7900727

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00922505T PT1163239E (pt) 1999-03-12 2000-03-08 Amidas de aminoacidos modificadas como antagonistas do cgrp

Country Status (13)

Country Link
EP (1) EP1163239B1 (pt)
JP (1) JP3719937B2 (pt)
AR (1) AR022906A1 (pt)
AT (1) ATE241616T1 (pt)
AU (1) AU4288000A (pt)
CA (1) CA2361939A1 (pt)
CO (1) CO5150226A1 (pt)
DE (2) DE19911039A1 (pt)
DK (1) DK1163239T3 (pt)
ES (1) ES2199819T3 (pt)
PT (1) PT1163239E (pt)
UY (1) UY26057A1 (pt)
WO (1) WO2000055154A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19937304C2 (de) * 1999-08-10 2003-08-21 Boehringer Ingelheim Pharma Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
US6521609B1 (en) 1999-08-10 2003-02-18 Boehringer Ingelheim Pharma Kg Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
DE19952147A1 (de) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO2003050109A1 (en) * 2001-12-12 2003-06-19 Eli Lilly And Company Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
KR20050008790A (ko) 2002-06-05 2005-01-21 브리스톨-마이어스 스큅 컴퍼니 칼시토닌 유전자 관련 펩티드 수용체 길항제
DE10227294A1 (de) * 2002-06-19 2004-01-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Zubereitungen zur intranasalen Applikation ausgewählter, von Aminosäuren abgeleiteter CGRP-Antagonisten sowie Verfahren zu deren Herstellung
DK1556020T3 (da) 2002-08-12 2009-06-22 Birkir Sveinsson Anvendelse af CGRP-antagonistforbindelser til behandling af psoriasis
US11517612B2 (en) 2016-11-18 2022-12-06 Nepsone Ehf Methods of treating inflammatory skin disorders
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
AR046787A1 (es) 2003-12-05 2005-12-21 Bristol Myers Squibb Co Agentes antimigrana heterociclicos
AU2003297694A1 (en) 2003-12-05 2005-08-12 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
DE102004006893A1 (de) * 2004-02-12 2005-09-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von 1[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
JP2007533685A (ja) * 2004-04-20 2007-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 偏頭痛を治療するためのセロトニン再吸収阻害剤と組合わせたcgrpアンタゴニストの使用
EP1619187A1 (de) * 2004-07-23 2006-01-25 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Herstellung von 3-(4-Piperidinyl)- 2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-on
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
US7491717B2 (en) 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
US7473778B2 (en) 2005-12-24 2009-01-06 Boehringer Ingelheim International Gmbh 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one
MX2010003849A (es) 2007-10-18 2010-04-27 Boehringer Ingelheim Int Antagonistas de cgrp.
EP2065381A1 (de) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP Antagonisten
CA2705405A1 (en) 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh New compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1440976B1 (de) * 1996-09-10 2008-07-23 Boehringer Ingelheim Pharma GmbH & Co.KG Abgewandelte Aminosäuren, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6552043B1 (en) * 1998-09-30 2003-04-22 Merck Sharpe & Dohme Ltd. Benzimidazolinyl piperidines as CGRP ligands

Also Published As

Publication number Publication date
EP1163239A1 (de) 2001-12-19
ES2199819T3 (es) 2004-03-01
DK1163239T3 (da) 2003-09-08
AR022906A1 (es) 2002-09-04
UY26057A1 (es) 2000-10-31
WO2000055154A1 (de) 2000-09-21
DE50002364D1 (de) 2003-07-03
JP3719937B2 (ja) 2005-11-24
DE19911039A1 (de) 2000-09-14
EP1163239B1 (de) 2003-05-28
ATE241616T1 (de) 2003-06-15
CA2361939A1 (en) 2000-09-21
CO5150226A1 (es) 2002-04-29
JP2002539208A (ja) 2002-11-19
AU4288000A (en) 2000-10-04

Similar Documents

Publication Publication Date Title
PT1163239E (pt) Amidas de aminoacidos modificadas como antagonistas do cgrp
PT1226110E (pt) Aminoacidos biciclicos como agentes farmaceuticos
PT1379511E (pt) Derivados de di-hidro-benzo[b] [1,4] diazepin-2-ona como antagonistas ii de r2glum
PT1244647E (pt) Derivados de quinazolina como inibidores de vegf
PT1379522E (pt) Derivados de di-hidro-benzo[b] [1,4] diazepina-2-ona como antagonistas i do r2glum
PT1117659E (pt) Cianoquinolinas substituidas como inibidores de tirosina-quinases de proteinas
DE60025345D1 (de) Spritzanordnung
PT1287001E (pt) Derivados de tiofeno uteis como agentes anticancerigenos
PT1084114E (pt) Derivados isotiazole uteis como agentes anticancerigenos
PT1164847E (pt) Heptapeptidos analogos de oxitocina
DE69924879D1 (de) Waschmittelformkörper
PT1177185E (pt) Derivados de 4, 5, 6, 7-tetra-hidroindazole como agentes antitumorais
PT1185529E (pt) Pirazolobenzodiazepinas como inibidores de cdk2
PT1021541E (pt) Mcp-2 truncadas na extremidade amino como antagonistas de quimiocina
DE50009261D1 (de) Einspritzventil
PT1163264E (pt) Novos antagonistas de lhrh com propriedades de solubilidade melhoradas
ES1044448Y (es) Auto-aplicador de vendaje
PT1023268E (pt) Isoquinolinas como inibidores de uroquinase
PT1216250E (pt) Derivados propilicos substituidos de tienoisoxazolil- e tienilpirrazolil-fenoxi uteis como antagonistas d4
NO20003694D0 (no) VLA-4 antagonister
PT964863E (pt) Oxazolidinonas como antagonistas de 5-ht2a
PT1181288E (pt) Oxazolidinonas biciclicas como agentes antibacterianos
PT1171419E (pt) Derivados de bifenilo como antagonistas do receptor da neuroquinina-1
PT1231211E (pt) Derivados de tiazolidinadiona como agentes antidiabeticos
PT1075471E (pt) Derivados de indolilo como agentes seronergicos